GeoVax Labs Inc
Follow $GOVX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $GOVX by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredsnapshot unavailable for GOVX. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is GOVX moving today?
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
GOVX overview
Related filings and maps
Congress activity in GOVX
No receipt-qualified filings found.
GOVX contract awards, year to date.
Public federal awards linked to this ticker.
GOVX lobbying filings, year to date.
Registered lobbying filings matched to GeoVax Labs Inc.